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Abstract
Objective: Developing evidenced-based practices for the management of childhood psychiatric disorders requires research
studies that address how to treat children during both the acute phase of the disorder and beyond. Given the selection of a
medication for acute treatment, discontinuation trials are used to evaluate the effects of treatment duration (e.g., time on
medication) and/or maintenance strategies following successful acute-phase treatment. Recently, sequential multiple as-
signment randomized trials (SMART) have been proposed for use in informing sequences of critical clinical decisions such as
those mentioned. The objective of this article is to illustrate how a SMART study is related to the standard discontinuation trial
design, while addressing additional clinically important questions with similar trial resources.
Method: The recently completed Child/Adolescent Anxiety Multimodal Study (CAMS), a randomized trial that examined
the relative efficacy of three acute-phase treatments for pediatric anxiety disorders, along with a next logical step, a standard
discontinuation trial design, is used to clarify the ideas. This example is used to compare the discontinuation trial design
relative to the SMART design.
Results: We find that the standard discontinuation trial can be modified slightly using a SMART design to yield high-quality
data that can be used to address a wider variety of questions in addition to the impact of treatment duration. We discuss how
this innovative trial design is ultimately more efficient and less costly than the standard discontinuation trial, and may result in
more representative comparisons between treatments.
Conclusions: Mental health researchers who are interested in addressing questions concerning the effects of continued
treatment (for different durations) following successful acute-phase treatment should consider SMART designs in place of
discontinuation trial designs in their research. SMART designs can be used to address these and other questions concerning
individualized sequences of treatment, such as the choice of a rescue treatment in case of postacute phase relapse.
Introduction
Developing evidenced based practices for the managementof childhood psychiatric disorders requires research studies
that address how to treat children during both the acute phase of the
disorder and beyond. There is currently a strong evidence base for
the efficacy/effectiveness of acute-phase treatments for most
common childhood and adolescent psychiatric disorders. Studies
are now needed that examine intervention approaches for achieving
continued response, remission, and sustained recovery following
successful acute treatment.
Discontinuation trials in psychiatry are commonly used to
evaluate the impact of treatments following successful acute-phase
treatment. In the standard discontinuation trial, all patients re-
cruited into the study are initially treated with an acute-phase
treatment. At the end of the acute period, treatment responders are
randomized to either discontinue treatment or continue with
treatment for specified durations. In the majority of discontinuation
trials, the primary outcome is the time to first relapse in the post-
acute phase. For example, Emslie et al. (2008) used a discontinu-
ation trial to answer the following question: ‘‘Among depressed
children and adolescents who acutely respond to 12 weeks of
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fluoxetine, what is the effect of immediately discontinuing medi-
cation versus discontinuation after an additional 12 weeks of
treatment on time to first relapse?’’
Assessing the impact of different treatment durations is often
the explicit and primary rationale for discontinuation trials. How-
ever, embedded within this rationale is the implicit assumption
that sequential, individualized decision making is essential for the
long-term management of chronic psychiatric disorders. This is
evident by the fact that discontinuation trials inform what to do
following acute-phase treatment (treatment sequencing), and in-
form how to treat participants who respond to both acute-phase
treatment and postacute phase treatment (a form of adaptive,
treatment individualization).
In childhood mental health treatment, sequential, individualized,
decision making is critical as some children respond well to a
particular treatment or length of treatment, whereas others do not. It
is often necessary to alter or modify ongoing treatment to achieve
maximum benefit or minimize risk/burden (Murphy et al. 2007a).
Moreover, not all children who respond initially will need to remain
on treatment, especially when considering the potential for adverse
events during chronic treatment. Adaptive treatment strategies
(ATSs) have been used to formalize the sequential, individualized
decision making that clinicians often use when providing treatment
in actual clinical practice (Lavori et al. 2000; Lavori and Dawson
2007, 2008; Murphy 2005; Murphy et al. 2007a, b, c; Murphy and
Almirall 2009). Discontinuation trials appear to provide the first
basic step for developing ATSs across the acute and postacute
treatment phases. However, the standard discontinuation trial does
not continue to follow participants who relapse, and, therefore,
results in a missed opportunity in terms of 1) understanding the
effect of treatment duration ATSs on long-term outcomes, and 2)
informing how to rescue relapsing participants.
Sequential Multiple Assignment Randomized Trials (SMARTs),
which will be discussed in more detail, were developed explicitly
for the purpose of developing ATSs (Murphy 2005; Nahum-Shani
et al. 2012). At the time of this writing, there are a number of
SMARTs currently being conducted in a variety of fields, such as
to develop ATSs for children with attention-deficit/hyperactivity
disorder (ADHD) (Pelham, personal communication; Nahum-
Shani et al. to appear), alcohol abuse (McKay, personal commu-
nication), and autism (Kasari, personal communication) and
substance abuse among pregnant women ( Jones, personal com-
munication), among others. Lei et al. (2011) describe the simi-
larities and differences among the four above-mentioned SMART
designs. The SMART designed in Thall et al. (2000), reported in
Thall et al. (2007), and later re-analyzed by Wang et al. (in press)
considers 12 ATSs in the treatment of prostate cancer. These
ATSs begin with one of four chemotherapies; participants who
respond to the initial chemotherapy remain on it, whereas par-
ticipants who fail to respond to the initial chemotherapy are
switched to one of the other three. Among the interesting findings
from this SMART is that the rescue treatment in one of the bet-
ter performing ATSs was a treatment that performed poorly if
provided initially.
This article examines the ‘‘missed opportunity’’ of the standard
discontinuation trial and proposes the use of the SMART as an
enhanced alternative to the standard discontinuation trials. Speci-
fically, we argue that SMARTs are ultimately less costly and more
efficient than standard discontinuation trials by maximizing the
amount of useful scientific information obtained in a single trial,
while still addressing the primary scientific aims of standard dis-
continuation trials.
To illustrate these concepts, we utilize the recently completed
Child/Adolescent Anxiety Multimodal Study (CAMS; Walkup
et al. 2008). First, we review the results of CAMS and for illus-
tration we provide an example of a standard discontinuation trial
that could follow CAMS. Then, we present ATSs and SMARTs,
and describe their relation to the standard discontinuation trial.
Then, we describe two ways to enhance the standard discontinua-
tion trial using a SMART. The final section offers a discussion.
CAMS and a Standard Discontinuation Trial
CAMS (Walkup et al. 2008) was a multisite, randomized
placebo-controlled trial that examined the relative efficacy of
cognitive behavioral therapy (CBT), sertraline (SRT), and their
combination (COMB) against pill placebo (PBO) for the treatment
of social anxiety disorder (SAD), generalized anxiety disorder
(GAD), and social phobia in children and adolescents between the
ages of 7 and 17. Four hundred eighty-eight participants were
randomly assigned to one of the four acute-phase treatment con-
ditions. At the end of 12 weeks of acute-phase treatment, investi-
gators reported an 80.7% response rate among participants treated
with COMB, a 59.7% among participants treated with CBT only,
54.9% among participants treated with SRT only, and a 23.7%
response rate among participants treated with PBO. In CAMS,
response was defined as a Clinical Global Impressions–Improve-
ment rating scale value of £ 2. The results of CAMS showed that
combination therapy (CBT + SRT), as well as the monotherapies
(CBT alone or SRT alone), constituted three effective treatments
(relative to no treatment) for a diverse population of children and
adolescents with three of the most common and disabling pediatric
and adolescent anxiety disorders.
Despite the success of the three active treatments reported in
CAMS, important public health questions remain unanswered
about long-term treatment of pediatric anxiety disorders. For ex-
ample, given the short duration of medication treatment in most
clinical trials (e.g., 12 weeks in CAMS) relative to the duration of
medication treatment reported in community settings (e.g., 25% of
9–18-year-old new antidepressant users may complete at least
6 months of medication treatment; Shireman et al. 2002), concerns
about side effects resulting from long-term medication exposure
(Homberg et al. 2010), reservations on behalf of parents about
medication use (Young et al. 2005, 2006), and the genuine need on
behalf of clinicians and parents alike about how best to maintain
symptom improvement, achieve remission, and prevent relapse,
lead to the following important questions:
1. ‘‘What is the impact of discontinuing SRT treatment versus
continuing SRT in children who respond to 12 weeks of
COMB treatment?’’
2. ‘‘Should the previous decision depend upon characteristics
of the child?’’
These, and similar questions, were described as significant public
health concerns even before the completion of CAMS (Pine 2002).
Discontinuation trials are intended primarily to address the timing
question (1), or from a parent’s perspective, ‘‘How long does my
child need to continue on medication now that she is better?’’
Further, secondary data analyses of discontinuation trials can in-
vestigate whether the impact on relapse rates of one discontinuation
strategy versus another depends upon child characteristics or child
outcomes collected during acute-phase treatment (2).
Figure 1A depicts a standard discontinuation trial that could
be viewed as the next logical step following the outcomes observed
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FIG. 1. (A) Example of a standard discontinuation trial. In standard discontinuation trials, relapsers (at any point) are removed from
further study. Partial Strategy A and Partial Strategy B are identical up to week 24. The primary aim is a comparison of Partial Strategy
A versus Partial Strategy B. This is equivalent to a comparison of time until relapse from week 24 onward, among responders up to week
24. (B) An alternate presentation of the standard discontinuation trial shown in (A). In standard discontinuation trials, relapsers (at any
point) are removed from further study. The primary aim discussed is a comparison of Treatment II versus Treatment III in terms of time
until first relapse. This is a comparison of time until relapse from week 24 onward, among responders up to week 24. SRT = sertraline
medication; CBT = cognitive behavioral therapy; COMB = SRT + CBT; CBT-BOOST = CBT booster sessions.
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in CAMS. This trial is designed to address the timing of SRT
discontinuation following successful acute-phase response to
COMB therapy in the context of once-monthly continued CBT
booster sessions (CBT-BOOST). CBT-BOOST is designed to
help patients manage minor stressors as medication is removed,
thereby potentially preventing the unnecessary restart of medi-
cation, and also identifying patients who are likely medication
dependent. In the treatment of obsessive-compulsive disorders,
expert guidelines recommend once-monthly CBT booster ses-
sions during medication discontinuation. (March et al. 1997). The
options to which participants are randomized in a standard dis-
continuation trial are only ‘‘partial’’ treatment strategies, because
they do not formally operationalize what to do for participants
who relapse. In this example trial, all participants receive 12
weeks of COMB treatment at baseline. Following 12 weeks, re-
sponders are then randomly assigned to one of three continuation-
phase treatment arms:
Partial Strategy A: Remain on SRT + CBT-BOOST for an
additional 24 weeks, then taper SRT while remaining on CBT-
BOOST;
Partial Strategy B: Remain on SRT + CBT-BOOST for an ad-
ditional 12 weeks, then taper SRT while remaining on CBT-
BOOST; or
Partial Strategy C: Taper SRT immediately while remaining on
CBT-BOOST.
This trial is intended primarily to compare time to first relapse
between different SRT duration times in the continuation phase. In
this example of a standard discontinuation trial (and in the alter-
native study designs we consider subsequently), we assume that all
participants can be followed for a maximum of 48 weeks (12 weeks
acute phase + 36 weeks continuation phase). In the standard dis-
continuation trial, once the primary outcome has been observed
(e.g., first relapse), participants are removed from further study.
ATSs and Discontinuation Trials
What is an ATS?
ATSs operationalize sequential, clinical decision making via a
sequence of decision rules, one per clinical decision. In the context
of ATSs, because the aim is to inform actual clinical practice,
‘‘treatment’’ is broadly defined to include all treatment manage-
ment or strategy decisions. Hence, the decision to ‘‘discontinue
SRT,’’ for example, is thought to be a ‘‘treatment.’’ Or, as another
example, if ‘‘SRT discontinuation’’ involves referral to the com-
munity where the patient might receive other concomitant treat-
ment, then the ‘‘treatment’’ is ‘‘SRT discontinuation with the
possibility of receiving community-based care.’’
The decision rules utilize patient characteristics and observed
patient outcomes to recommend whether, how, or when to alter the
intensity, type, or delivery of treatment (Lavori et al. 2000; Collins
et al. 2005; Murphy 2005; Murphy et al. 2007b; Lavori and Dawson
2007, 2008;). An example of a two-decision point, continuation-
phase ATS among patients with anxiety disorders following re-
sponse to 12 weeks of acute phase COMB treatment is shown in
Figure 2.
In this simple ATS, responders to 12 weeks acute-phase COMB
treatment (SRT + CBT) continued on the medication sertraline
(SRT) while tapering CBT to monthly CBT booster sessions for an
additional 12 weeks. At the end of 24 weeks, those participants who
continued to show a positive treatment response were tapered off
SRT while continuing to receive monthly CBT booster sessions for
an additional 12 weeks. However, participants who relapsed at any
point during weeks 12–24, restarted COMB treatment for an ad-
ditional 12 weeks. This ATS addressed two critical decision points
during the continuation phase: First, it addressed which treatment
to provide during weeks 12–24; and second, given either continued
response, or relapse, it addressed which treatment to provide next
(during weeks 24–36 for responders; and up to week 36 for re-
lapsers, depending upon the time of relapse).
From the perspective of the clinician, this ATS is a guide (i.e., a
decision tree, as depicted in Fig. 2) for decision making at two
critical decision points in the continuation phase. The assessment
used to measure response/relapse during weeks 12–24 in Figure 2 is
known as a tailoring variable, because future treatment is tailored
(e.g., individualized) depending upon its value. In this ATS, relapse
(or early signs of nonresponse) can be defined as meeting a criterion
on the Clinical Global Impressions (CGI) scale (e.g., three or more
on the CGI) or some other symptom measure collected during or
after the initial continuation-phase treatment. From the perspective
of the patient, an ATS is just a sequence of treatments. For example,
a child who responds to acute-phase 12 week COMB treatment and
continues to respond to SRT + CBT-BOOST during weeks 13–24,
that child’s complete assigned continuation-phase treatment se-
quence is (SRT + CBT-BOOST weeks 13–24 followed by CBT-
BOOST only weeks 25–36).
FIG. 2. A continuation-phase adaptive treatment strategy among responders to acute-phase treatment. SRT = sertraline medication;
CBT = cognitive behavioral therapy; COMB = SRT + CBT; CBT-BOOST = CBT booster sessions.
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Two characterizing features of the standard
discontinuation trial
Although rarely stated explicitly, developing ATSs is one of the
main reasons for conducting discontinuation trials in mental health
research. This is evident from three characterizing features of the
standard discontinuation trial design and analysis. First, the dis-
continuation trial is fundamentally concerned with how treatments
should be sequenced, for example, acute-phase COMB followed by
continuation-phase CBT-BOOST only (i.e., discontinue SRT).
Second, in standard discontinuation trials, subjects who respond
to the acute-phase treatment are randomized to two or more
continuation-phase treatment alternatives. This study design choice
reflects the fact that discontinuation trials are designed to inform
the first critical decision about what to do following a successful
initial, acute-phase treatment response. Third, in standard discon-
tinuation trials, the continuation-phase treatment alternatives to
which participants are randomized usually constitute different
durations of the same treatment. This study design choice reflects
the fact that discontinuation trials inform whether treatment should
continue among those patients who are responding earlier in the
continuation phase.
To better appreciate the third point, it is instructive to view the
standard discontinuation trial reconfigured as a trial with a se-
quence of randomizations, one per critical decision. In Figure 1B,
there are conceptually two randomizations: The first, for respond-
ing participants at week 13, to either continue treatment or dis-
continue treatment; and the second, for responding participants at
week 25, to continue or discontinue treatment.
The discontinuation trial in Figure 1B, although it appears more
complicated, is essentially identical to the trial depicted in Figure
1A. For example, a comparison of the time to first relapse between
participants randomized to Partial Strategies A and B in Figure 1A
is effectively a comparison of the time to first relapse between
participants randomized to Treatment I followed by II versus those
randomized to treatment I followed by treatment III in Figure 1B.
This follows because in the trial in Figure 1A, participants in the
two arms, Partial Strategy A and Partial Strategy B, are on the same
treatment during the first 12 weeks.
The missed opportunity in the standard
discontinuation trial
In the standard discontinuation trial, participants are removed
from further study immediately after their first relapse; this can
occur at any stage in the course of the experiment. From our per-
spective, this is a critical methodological weakness of this design,
as it leads to a missed opportunity by prohibiting investigators
to study how to clinically manage those who relapse while on
postacute-phase treatment.
To better appreciate this issue, consider the following. First,
discarding participants who relapse implicitly assumes that the only
outcome of interest is time to first relapse, as all other outcomes are
missing (by design) once a participant fails to respond. This
eliminates the ability of investigators to examine the impact of
treatment discontinuation on other longitudinal outcomes (for ex-
ample, trajectory of longitudinal symptom counts, side effects,
possible rescue treatments). This shortcoming is problematic in the
context of childhood mental health in which symptoms often wax
and wane (Wittchen et al. 2002), and a variety of contextual factors
often contribute to a relapse (e.g., stress of entering a new school
year). It is important to understand the trajectory of outcomes be-
yond the initial relapse.
Second, once participants are removed, the opportunity to
characterize how those who relapse might respond longitudinally
on rescue treatment(s) is lost. For example, a longer duration of the
acute treatment might make it easier to rescue patients who have
relapsed than a shorter duration of acute treatment; however this
question cannot be addressed in the traditional discontinuation
design because investigators ‘‘disenroll’’ participants who relapse.
That is, by design the standard discontinuation trial does not pro-
vide the data to assess the cumulative (or synergistic) effects of
sequenced treatment decisions. This is a critical shortcoming, given
that the development and evaluation of effective interventions for
children who are treatment refractory is a public health priority.
Third, the practice of removing participants who relapse is not
resource effective. This study design choice necessitates the exe-
cution of separate trials to investigate treatment options among
participants who relapse in the continuation phase. However, in-
vesting additional resources to recruit an entirely new sample of
relapsed participants to answer these questions is not an efficient
use of limited research resources.
Fourth, and perhaps most important, the conduct of a separate
trial for participants who relapse may lead to misleading results.
The recruited sample of relapsed participants may differ from the
population of patients who relapse after successful acute treatment.
For example, the recruited sample may include a higher fraction of
children with parents that are highly motivated and less likely to be
discouraged by the relapse than the population at large. Higher
motivation/lower levels of discouragement might lead to higher
adherence to the rescue treatment. In this example, to the extent that
family motivation influences child outcomes, the results of a sep-
arate trial on relapsed participants will not reflect the population
effect of the available rescue treatments. Moreover, even when
separate trials are conducted among those who relapse in the con-
tinuation phase, they do not allow investigators to observe the total
effect of an initial continuation treatment, including the delayed (or
‘‘downstream’’) effects mentioned previously.
Moving Beyond the Standard Discontinuation
Trial Design
Improving the discontinuation trial
using SMARTer designs
A discontinuation trial design that follows all participants (in-
cluding those who relapse) and/or evaluates potential rescue
treatments among postacute-phase relapsers would make better use
of trial resources and offer enhanced scientific opportunities. Such a
trial would allow investigators to fully inform the development of
continuation-phase ATS. Further, it would increase the number and
types of scientific questions that could be answered in a single study
design while still permitting the investigators to examine the
original treatment discontinuation question(s), without altering the
primary outcome analysis (time to first relapse).
We propose two improvements to the standard discontinuation
trial. Both proposals constitute a Sequential Multiple Assignment
Randomized Trial (SMART; Lavori and Dawson 2000; Murphy
2005; Lavori and Dawson 2007; Murphy et al. 2007c; Oetting et al.
2007). Both SMART proposals have these features: 1) participants
are randomized multiple times over the course of a trial—that is, at
each critical decision point—in order to experimentally evaluate
which is the most appropriate treatment at each critical decision
point, and 2) all participants are followed through the end of the
trial to provide investigators the opportunity to evaluate and com-
pare a variety of longitudinal outcomes (not just time to relapse)
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under different ATSs. The standard discontinuation trial, exem-
plified by Figure 1, possesses feature 1 but not feature 2.
SMARTer Design A
In this design, participants who relapse at any point during the
continuation phase are followed by the investigative team and
undergo regularly scheduled outcome assessments until the end of
the study. A rescue treatment for participants who relapse is de-
livered in a protocol-driven way (i.e., manualized) or if partici-
pants are referred out to community providers (i.e., treatment
provided by a non-study clinician), the referral process is man-
ualized and the treatment received in the community is docu-
mented. Figure 3A is an example of this SMART. Here,
participants who relapse in the continuation phase return to COMB
(a treatment known to have worked in the acute phase for this
population). Note that this proposal involves only a minimal
change from the standard discontinuation trial (Fig. 1B). Those
participants who fail to respond are offered COMB treatment and
continue to be followed in the trial. Regularly scheduled assess-
ments should include detailed information about all treatments
received over the full course of the trial, rather than solely up to
the point of initial nonresponse, as is common in standard dis-
continuation trials.
Unlike the standard discontinuation trial (Fig. 1), the proposed
SMARTer Design A (Fig. 3A) would allow investigators to ad-
dress, for example, the following question: ‘‘Among responders
through week 24 on continued SRT + CBT-BOOST, do the
symptoms over the succeeding 12 weeks (weeks 24–36) vary be-
tween participants randomized to continue SRT (Treatment II)
versus those randomized to discontinue SRT (Treatment III)?’’
In addition to evaluating longitudinal symptoms, another im-
portant benefit of following SMARTer Design A (Fig. 3A) is that it
provides investigators the ability to evaluate longitudinal outcomes
for each of several ATSs. For example, the proposed design in
Figure 3A includes three embedded continuation-phase ATSs. The
three ATSs are:
ATS 1: Continue SRT + CBT-BOOST for 12 additional weeks.
If the child continues to respond through week 24, then maintain
SRT + CBT-BOOST for yet another 12 weeks; otherwise, if the
child relapses anytime between week 12 and week 24, then im-
mediately re-initiate COMB (SRT + full-protocol CBT).
ATS 2: Continue SRT + CBT-BOOST for 12 additional weeks.
If the child continues to respond through week 24, then step down
treatment to CBT-BOOST alone (by discontinuing SRT) for an
additional 12 weeks; otherwise, if the child relapses anytime
between week 12 and week 24, then re-initiate COMB.
ATS 3: Step down treatment to CBT-BOOST only (by dis-
continuing SRT medication) for first 12 weeks in the continu-
ation phase. If the child continues to respond through week 24,
then maintain CBT-BOOST only for an additional 12 weeks;
otherwise, if the child relapses anytime between week 12 and
week 24 after SRT discontinuation (with CBT-BOOST), then
re-initiate COMB.
Note that ATS 2 is the example ATS shown in Figure 2. In
contrast, the standard discontinuation trial (Fig. 1B) does not in-
clude any one of these ATSs, because participants who relapse are
‘‘disenrolled’’ from the trial. Further, note that because the standard
discontinuation trial design is embedded in the SMART in Figure
3A, it allows investigators to examine the original discontinuation
question.
SMARTer Design B
This proposal builds upon the SMARTer Design A. It can be
used to provide evidence for which treatment to provide to par-
ticipants who relapse in the continuation phase. Here, participants
who relapse after having discontinued SRT in the continuation
phase are re-randomized between two rescue treatment options
(Fig. 3B). This SMART study enjoys all of the advantages of the
SMART in Figure 3A, plus it allows the investigator to experi-
mentally address the following rescue treatment question: ‘‘Among
children who respond to 12 weeks of acute-phase COMB treatment,
yet relapse by week 24 after stepping down to CBT-BOOST alone
(by discontinuing SRT), what is the difference in longitudinal
outcomes between children assigned to re-initiate to COMB
(Treatment VII) versus those children assigned to switch to SRT
alone (Treatment VIII)?’’ This question asks whether it is necessary
to continue CBT or switch to medication as part of the rescue
therapy. Further, the trial shown in Figure 3B has the added benefit
of providing data on yet a fourth ATS, namely:
ATS 4: Step-down treatment by discontinuing medication
while continuing CBT booster sessions for the first 12 weeks of
the continuation phase. If the child continues to respond
through week 24, then maintain CBT booster sessions only (no
medication) for an additional 12 weeks. Otherwise, if the child
relapses anytime between week 12 and week 24 after medica-
tion discontinuation, then switch to SRT alone (without CBT).
The design described in Figure 3B is used to illustrate and
highlight the important point that subsequent randomizations in a
SMART do not have to be only among responders (as in the
standard discontinuation trial). SMARTs allow investigators to
examine the efficacy/effectiveness of treatment options among
responders and nonresponders alike.
The decision between the trial in Figure 3A versus the trial in
Figure 3B will depend upon a variety of factors, including feasibility
and cost. For example, in the context of our example, one important
factor is the number of participants expected to relapse under the
initial SRT discontinuation (CBT-BOOST alone after the acute
phase). If an insufficient number of children are expected to relapse
during the continuation phase, then re-randomizing nonresponders
will not provide sufficient data to compare rescue treatments for
nonresponders; in this case, the trial in Figure 3A is more appro-
priate. Subsequently, we discuss sample size considerations.
Additional Advantages of the Proposed SMARTer
Designs over the Standard Discontinuation Trial
Conducting a SMART as opposed to a standard discontinuation
trial has a variety of other important advantages.
Is ultimately more resource effective
It may appear that the proposed SMARTs are more costly rel-
ative to the standard discontinuation trial because of the added
expense of 1) following all participants over the full course of the
trial, and 2) potentially delivering multiple treatments for relapsing
participants. With respect to 1), standard discontinuation trial
personnel costs already account for a follow-up over the full course
of the trial, as it is not possible to know ahead of time at what point
during the study participants will relapse. Indeed, this is the primary
outcome of the standard discontinuation trial!
With respect to 2), yes, there are additional costs incurred by
providing additional treatments. However, these additional costs
SMARTer DISCONTINUATION TRIALS 369
FIG. 3. (A) A SMART that builds on the standard discontinuation trial. The primary aim is a comparison of Treatment II versus
Treatment III in terms of time until first relapse. This is a comparison of time until relapse from week 24 onward, among responders up
to week 24. (B) A SMART that improves the standard discontinuation trial. The primary aim is a comparison of Treatment II versus
Treatment III in terms of time until first relapse. This is a comparison of time until relapse from week 24 onward, among responders up
to week 24. SMART, sequential multiple assignment randomized trials; SRT = sertraline medication; CBT = cognitive behavioral
therapy; COMB = SRT + CBT; CBT-BOOST = CBT booster sessions.
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must be placed within the context of the additional knowledge that
will be gained in a trial such as the ones proposed, in particular by
avoiding the design and execution of separate trials. The current
approach to conducting clinical trials typically involves one trial to
answer a discontinuation question and then a separate trial, often
with a new sample of participants, to investigate which rescue
treatment is most effective for patients who relapse. Therefore, the
total cost associated with the traditional way may be significantly
higher.
Permits a variety of interesting hypothesis-generating
analyses
The multiple randomizations in the SMART support a variety
of interesting secondary analyses. Considering Figure 3B, it is
plausible that continuing SRT + CBT-BOOST in the postacute
phase (Treatment I) results in lower relapse rates than for CBT-
BOOST alone (Treatment V) in the short term (e.g., by week 24).
However, in the context of the provided maintenance and rescue
treatments, participants administered CBT-BOOST alone initially
(Treatment V) may have an overall better symptom management
at week 48. That is, it is possible that the movement of early
relapsing participants from initial CBT-BOOST alone to COMB
(full CBT + medication) enhances the durability of the skills ac-
quired during acute-phase CBT, and thus leads to improved
symptom scores at 48 weeks. On the other hand, participants who
were initially assigned SRT + CBT-BOOST (Treatment I) and
either did not relapse or relapsed very late in the study (i.e., did
better in the shorter term), might never receive the opportunity to
consolidate their CBT skills. The standard discontinuation trial
does not allow investigators to investigate these delayed (or
downstream) effects because it is not designed to evaluate treat-
ments in sequence.
As a second example, suppose that some initial treatments elicit
outcomes in the intermediate stages that may be used to better
individualize future treatments and, in turn, produce more positive
effects over the longer term. Considering Figure 3B, removing SRT
at 12 weeks postacute phase may serve to diagnose participants
who are ‘‘medication dependent’’ (i.e., show a quick rise in
symptoms caused by SRT removal). This information (quicker rise
versus slower rise in symptoms following SRT removal) may then
be used in secondary analyses to determine the types of participants
who should restart medication only, versus re-initiating COMB.
The result is that the act of discontinuing medications may not have
had therapeutic effect in the short term, per se, but helped identify
individuals of a certain type (in this case, the medication-dependent
type) whose future treatment could then be better individualized.
SMARTs allows investigators to study these prescriptive effects,
whereas the discontinuation trial does not.
Ensures balance to subsequent treatment
randomizations
The standard discontinuation trial randomizes participants up
front to three or more discontinuation regimes, even when some of
these regimes differ only in the later weeks (for example, Partial
Strategies A and B in Figure 1A are identical over the first 12 weeks
postacute-phase, i.e., through week 24). One benefit of the se-
quential randomization is that it allows investigators to incorporate
both baseline and intermediate outcome measures (up to the point
of the subsequent critical decision point) to reduce chance imbal-
ance in subsequent treatment offerings. For example, as in Figure
3A, the randomization to Treatment II or III at week 24 can be
stratified by adherence and other outcomes collected over the
course of the trial through week 24.
Enhances generalizability and recruitment
Because participants understand that treatment will be adapted
to their needs over the course of the full trial—akin to what happens
in actual clinical practice—a more representative group of partic-
ipants is likely to participate in a SMART. This enhances the het-
erogeneity of the sample, which improves the trial’s external
validity and its ability to identify predictors (both participant
characteristics and time-varying measures) of treatment response.
SMART designs are likely (although we currently have only an-
ecdotal data to support this assertion) to attract a greater variety of
participants given that families are informed at the outset that their
child will be treated sequentially: that is, if the first assigned
treatment is not effective, then another treatment will be offered.
SMARTs Do Not Require Larger Sample Sizes
SMART designs do not necessarily require larger sample sizes
than do discontinuation trials. As in all randomized clinical trials,
the choice of the primary research question (aim) determines
sample size. The SMART alternatives given in Figure 3 can be
sized/powered to address the very same ‘‘time to first relapse’’
primary question typically used to size/power the standard dis-
continuation trial design (Fig. 1).
As a concrete example, suppose the primary aim of the standard
discontinuation trial in Figure 1 is to examine, in terms of time to
first relapse, the impact of continuing SRT + CBT-BOOST (the
SRT continuation group) at week 24 versus beginning CBT-
BOOST only (the SRT discontinuation group) at week 24 among
children who continue to respond to 24 weeks of COMB treatment.
This is a two-group comparison of Partial Strategy A versus Partial
Strategy B in Figure 1A. (In addition to being of scientific interest,
this is a natural primary comparison because it ensures sufficient
power to detect differences between Partial Strategies A versus C
and between B versus C, which usually have larger effect sizes.) In
Figures 1B and 3A and B, this primary aim is a two-group ran-
domized comparison of time until relapse (beginning at week 24,
and onward) between participants who are assigned Treatment II
versus those assigned Treatment III. The sample size calculation
for a two-group comparison of time to relapse can be based on the
log-rank test (Bland and Altman 2004), e.g., using SAS PROC
POWER (SAS Institute 2008) with the TWOSAMPLESURVIVAL
and test = logrank options.
Under standard assumptions, the total sample size for the
SMART in Figure 3A or B is 239 children and adolescents. The
number 239 is derived as follows: First, 56 responding participants
are required at week 24 for a comparison of Treatment II versus
Treatment III under the assumptions of a 1:1 randomization, ex-
ponentially distributed relapse distributions for both groups with an
80% continued response rate for the SRT + CBT-BOOST group
and a 60% continued response rate for the CBT-BOOST only group
at the end of week 36 (a 20% difference in survival at the end of
week 36, or hazard ratio of 2.29), a type I error rate of 5%, and 80%
power. Additional assumptions include a uniform participant ac-
crual period of 160 weeks (3 years of recruitment), and a follow-up
period of 24 weeks after the week 24 randomization, for a total of
48 weeks of study per participant as shown in the figures.
To obtain the 56 participants at week 24, 150 participants are
needed to enter the continuation phase at week 12; this calculation
assumes a 75% continued response rate at the end of week 24 and a
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1:1 randomization at week 12 to Treatment I versus Treatment IV,
that is, 2 · 56/0.75 = 2 · 75 = 150. Next, to obtain the 150 partici-
pants at week 12, 215 participants need to enter the acute phase
(COMB); this calculation assumes a 70% response rate at the end of
the acute-phase period (a conservative assumption based on the
80% acute-phase response rate for COMB, as reported in CAMS),
that is, 150/0.70 = 215. Further inflating this sample size to account
for 10% study dropout, a total of n = 215/0.90 = 239 children and
adolescents would have to be recruited. This is the total sample size
required for any of the three studies (Figs. 1 and 3A or B) in order to
address the primary question mentioned previously, recalling that
for any of the three studies considered, the data analysis for this
primary question is the same.
Although the sample size for a clinical trial is always determined
by the primary aim, it is often of interest to examine the resulting/
implied power to test secondary hypotheses/aims. For purposes of
the additional calculations given subsequently, we use the effective
sample size (i.e., 215 entering the acute phase, or 150 entering the
continuation phase), which already accounts for dropout. In a
standard discontinuation trial such as the one shown in Figure 1A, a
typical secondary question may be ‘‘Among children and adoles-
cents who acutely respond to 12 weeks of COMB, what is the effect
of discontinuing medication (CBT-BOOST only) versus continu-
ing medication (SRT + CBT-BOOST) at week 12 on time to first
relapse?’’ All three studies (Figs. 1 and 3A and B) are able to
address this question: In Figure 1A, this is a comparison of Partial
Strategies A + B versus Partial Strategy C, whereas in Figures 1B
and 3A and B, this is a comparison of all participants beginning on
Treatment I versus all participants beginning on Treatment IV.
Based on the sample calculations provided previously, with 150
participants randomized at week 12 (entering the continuation
phase), we can detect a difference of at least 12% in the survival
rate (continued response) at week 24 (e.g., a 75% response in the
SRT + CBT-BOOST continuation group versus £ 63% in the CBT-
BOOST only discontinuation group, or a hazard ratio of ‡ 1.62)
with 80% power.
Several interesting secondary questions that cannot be addressed
by the standard discontinuation trial design, but can be addressed
by the SMART design are as follows: First, consider the secondary
question ‘‘Among children and adolescents who acutely respond to
12 weeks of COMB, what is the effect of discontinuing medication
(CBT-BOOST only) versus continuing medication (SRT + CBT-
BOOST) at week 12 on the longitudinal change in anxiety symp-
toms between week 12 and week 48?’’ This question cannot be
answered by the standard design because not all participants
are followed for the full 48 weeks, whereas it can be answered by
the two SMART designs shown in Figure 3A and B. In Figure 3A
and B, this is a two-group longitudinal comparison of all partici-
pants initially assigned to Treatment I versus all participants ini-
tially assigned to Treatment V, in terms of longitudinal outcomes
from week 12 onward. A common outcome measure for this type of
question in child anxiety research is the continuous Pediatric An-
xiety Rating Scale (PARS; RUPP Anxiety Group 2002). Based on
the calculations given previously, with 150 participants random-
ized at week 12 (entering the continuation phase), assuming a 0.30
within-person correlation in PARS (based on the CAMS data),
Type I error rate of 5%, and 80% power, we can detect a small-
to-moderate effect size (Cohen 1988) of 0.44, which translates to a
clinically significant difference of 2.9 units on the PARS (based on
SD = 6.6 using the CAMS data).
Second, suppose that investigators are interested in documenting
the value of rescue treatments among children and adolescents who
acutely respond to 12 weeks of COMB and who discontinue
medication at week 12 (CBT-BOOST only), but subsequently re-
lapse by week 24. This type of question cannot be addressed by the
standard discontinuation trial design because these children are
removed from the study. However, it can be examined (albeit in two
different ways) by the two proposed SMART designs. Investigators
may choose between the SMARTer Figure 3A design versus the
SMARTer Figure 3B design. Using the former design (Fig. 3A),
investigators can estimate the fraction of relapsing children who are
rescued by re-initiation of COMB. Using the latter design (Fig. 3B),
investigators can make a randomized comparison of the two rescue
treatments (VII: re-initiate COMB or VIII: re-initiate medication
only) among children who had discontinued medication at week 12
and relapsed by week 24. The data analysis here would be a
between-groups (VII vs. VIII) comparison of change in PARS
from week 24 to week 48. To decide between the design in Figure
3A and the design in Figure 3B, consideration of the anticipated
relapse rate by week 24 the minimum detectable effect size
between the two rescue treatments evaluated in the Figure 3B
design is useful. In general, the higher the rate of relapse and larger
the minimum detectable effect size, the easier it is to justify using
the Figure 3B design over the Figure 3A design. Based on the
calculations given previously, 150/2 = 75 participants will be ran-
domized initially to CBT-BOOST only (Treatment V in Figs. 3A
and B). As mentioned, assuming a 0.30 within-person correlation in
PARS (based on the CAMS data), type I error rate of 5%, 80%
power, and relapse rates ranging from 40% (15 randomized to each
rescue treatment in Fig. 3B) to 70% (26 randomized to each rescue
treatment), the minimum detectable effect size ranges from 0.52
(moderate) to 0.70 (large). These effect sizes translate into between
rescue treatment group changes of 3.47–4.63 units on the PARS.
Typically, a change of at least 4 units on the PARS is considered
clinically meaningful. Therefore, if relapse rates of ‡ 60% are
expected by week 24 on initial medication discontinuation
(Treatment V), then the design in Figure 3B may be justifiable;
otherwise, the design in Figure 3A is preferred.
Third, a further secondary aim might be to select the best among
the ATSs embedded in the SMART (Oetting et al. 2007). As dis-
cussed, the design in Figure 3A has three ATSs; whereas the design
in Figure 3B has four ATSs. Based on the results in Oetting et al.
(2007), a sample size of 150 is sufficient for choosing the best ATS
with high probability (* 80%) when the best two ATSs differ by
moderate effect sizes or larger. Again, this is an example of a
secondary question that cannot be examined in the standard dis-
continuation trial, but can be addressed by the proposed SMARTer
alternatives.
Discussion
Other variations of the SMART design besides the two discussed
here are possible. In this article, we have focused on these two
choices because they represent two simple adaptations of the
standard discontinuation trial, yet provide additional hypothesis-
generating analyses concerning the individualization and se-
quencing of treatments, with relatively little additional logistical or
cost considerations relative to the amount of scientific knowledge
to be gained.
After examining the primary aims of a SMART, investigators
may use extensions of modern regression methods such as Q-
Learning (Nahum-Shani et al. to appear), to develop more richly
tailored ATSs. The resulting ATSs exhibit greater individualization
than do the ATSs embedded in the SMART. For example,
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investigators may learn in subsequent data analyses that adherence
during the postacute treatment continuation phase is important for
deciding both whether or not to discontinue treatment after week 24
and which rescue treatment to provide if the participant relapses.
SMARTs constitute an important part of the developmental, or
phased, approach to experimentation (Collins et al. 2005). This
means that after examining the primary and secondary scientific
questions in a SMART, and after developing a more richly tailored
ATS using data arising from a SMART, a ‘‘fully optimized ATS’’
can be compared against usual care, standard care, or other prom-
ising treatments in a follow-up two-group (or more) randomized
clinical trial.
Conclusions
Discontinuation trials have been used in psychiatry to answer
important clinical questions, such as how long to provide a given
treatment. In this article, we suggest that the implicit motivation for
executing a discontinuation trial is to inform individualized se-
quences of treatment decisions, that is, ATSs, for use in the man-
agement of mental health disorders. A weakness of the standard
discontinuation trial is that it does not allow investigators to de-
velop, examine, or compare sequences of treatment decisions over
the course of the postacute phase of treatment. In essence, by re-
moving nonresponders from further study, the standard discontin-
uation trial fails to yield data that can be used to shed light on how
to treat this population. We showed how the standard discontinu-
ation trial can be modified and significantly improved to yield data
that can better construct ATSs. In particular, we showed how the
primary questions addressed in a standard discontinuation trial can
also be addressed by embedding the standard discontinuation trial
within a SMART.
The innovative SMART design is ultimately more efficient and
less costly than the standard discontinuation trial, and it is more
attractive scientifically because of the additional scientific ques-
tions that it allows the investigator to address.
Clinical Significance
SMARTs are broadly applicable in any settings in which in-
vestigators are interested in developing an ATS for optimizing and
individualizing (i.e., personalizing) treatment over time. This ar-
ticle will be of interest to clinical investigators who are interested in
deriving more information out of a standard discontinuation trial. In
this context, SMARTs can be used to address clinically significant
questions such as ‘‘When to discontinue treatment following acute-
phase response?’’ and ‘‘Which treatment to provide given a relapse
following treatment discontinuation?’’
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